Research ArticleOpen AccessGoogle Scholar indexed
Nusinersen as a Leading Therapy for Spinal Muscular Atrophy: A Bibliometric Analysis of Leading Treatments
ThinkNeuro, LLC, Sacramento, CA, USA
ThinkNeuro, LLC, Sacramento, CA, USA
School of Neuroscience, College of Science, Virginia Tech, Blacksburg, VA, USA
Department of Biomedical Engineering, College of Engineering, University of North Texas, Denton, TX, USA
Department of Kinesiology, College of Health and Human Services, California State University, Fresno, CA, USA
Cox Mill High School, Concord, NC, USA
Fairfax High School, Fairfax, VA, USA
ThinkNeuro, LLC, Sacramento, CA, USA
ThinkNeuro, LLC, Sacramento, CA, USA
- 1 ThinkNeuro, LLC, Sacramento, CA, USA
- 2 ThinkNeuro, LLC, Sacramento, CA, USA
- 3 School of Neuroscience, College of Science, Virginia Tech, Blacksburg, VA, USA
- 4 Department of Biomedical Engineering, College of Engineering, University of North Texas, Denton, TX, USA
- 5 Department of Kinesiology, College of Health and Human Services, California State University, Fresno, CA, USA
- 6 Cox Mill High School, Concord, NC, USA
- 7 Fairfax High School, Fairfax, VA, USA
- 8 ThinkNeuro, LLC, Sacramento, CA, USA
- 9 ThinkNeuro, LLC, Sacramento, CA, USA
Copy link · social · email
Abstract
Spinal muscular atrophy (SMA) is a genetic disorder caused by mutations in the SMN1 (survival motor neuron 1) gene, leading to muscle weakness and impaired motor function. SMA generally affects infants and children but can develop during adulthood. Well-researched treatments such as nusinersen, onasemnogene abeparvovec-xioi, and risdiplam aim to restore SMN protein and improve patient outcomes. In order to identify research trends, leading therapies, and clinical outcomes for SMA, a bibliometric analysis of the 100 most-cited articles on SMA treatments in Web of Science (WoS) was performed. Nusinersen emerged as the most frequently studied treatment, with robust evidence supporting its role in improving patient quality of life and outlook. The bibliometric insights gathered may inform future research directions and support clinicians and patients in evidence-based decision-making.
KeywordsSpinal Muscular AtrophyPatient-Reported Outcomesand Treatments
- Aponte Ribero, V., Martí, Y., Batson, S., Mitchell, S., Gorni, K., Gusset, N., et al. (2023) Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures. Neurology , 101, e2103-e2113. https://doi.org/10.1212/wnl.0000000000207878
- Day, J.W., Howell, K., Place, A., Long, K., Rossello, J., Kertesz, N., et al. (2022) Advances and Limitations for the Treatment of Spinal Muscular Atrophy. BMC Pediatrics , 22, Article No. 632. https://doi.org/10.1186/s12887-022-03671-x
- Angilletta, I., Ferrante, R., Giansante, R., Lombardi, L., Babore, A., Dell’Elice, A., et al. (2023) Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. International Journal of Molecular Sciences , 24, Article 14873. https://doi.org/10.3390/ijms241914873
- Antonaci, L., Pera, M.C. and Mercuri, E. (2023) New Therapies for Spinal Muscular Atrophy: Where We Stand and What Is Next. European Journal of Pediatrics , 182, 2935-2942. https://doi.org/10.1007/s00431-023-04883-8
- Chaytow, H., Faller, K.M.E., Huang, Y. and Gillingwater, T.H. (2021) Spinal Muscular Atrophy: From Approved Therapies to Future Therapeutic Targets for Personalized Medicine. Cell Reports Medicine , 2, Article ID: 100346. https://doi.org/10.1016/j.xcrm.2021.100346
- Brkušanin, M., Kosać, A., Branković-Srećković, V., Jovanović, K., Perić, S., Karanović, J., et al. (2024) Phosphorylated Neurofilament Heavy Chain in Cerebrospinal Fluid and Plasma as a Nusinersen Treatment Response Marker in Childhood-Onset SMA Individuals from Serbia. Frontiers in Neurology , 15, Article 1394001. https://doi.org/10.3389/fneur.2024.1394001
- Day, J.W., Finkel, R.S., Chiriboga, C.A., Connolly, A.M., Crawford, T.O., Darras, B.T., et al. (2021) Onasemnogene Abeparvovec Gene Therapy for Symptomatic Infantile-Onset Spinal Muscular Atrophy in Patients with Two Copies of SMN2 (STR1VE): An Open-Label, Single-Arm, Multicentre, Phase 3 Trial. The Lancet Neurology , 20, 284-293. https://doi.org/10.1016/s1474-4422(21)00001-6
- Chongmelaxme, B., Yodsurang, V., Vichayachaipat, P., Srimatimanon, T. and Sanmaneechai, O. (2024) Gene-Based Therapy for the Treatment of Spinal Muscular Atrophy Types 1 and 2: A Systematic Review and Meta-Analysis. Gene Therapy , 32, 301-330. https://doi.org/10.1038/s41434-024-00503-8
- Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y. and Awano, H. (2023) Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. International Journal of Molecular Sciences , 24, Article 11939. https://doi.org/10.3390/ijms241511939